EFM
E Fund Management Portfolio holdings
AUM
$2.1B
1-Year Return
23.31%
This Quarter Return
+11.44%
1 Year Return
+23.31%
3 Year Return
+155.42%
5 Year Return
–
10 Year Return
–
AUM
$1.81B
AUM Growth
+$194M
(+12%)
Cap. Flow
+$44.6M
Cap. Flow
% of AUM
2.46%
Top 10 Holdings %
Top 10 Hldgs %
63.7%
Holding
392
New
24
Increased
176
Reduced
102
Closed
74
Top Buys
| 1 |
Futu Holdings
FUTU
|
$31.5M |
| 2 |
Applied Materials
AMAT
|
$29.1M |
| 3 |
Apple
AAPL
|
$15.5M |
| 4 |
Microsoft
MSFT
|
$12.6M |
| 5 |
NVIDIA
NVDA
|
$11.6M |
Top Sells
| 1 |
Advanced Micro Devices
AMD
|
$28.5M |
| 2 |
TSMC
TSM
|
$15.1M |
| 3 |
KE Holdings
BEKE
|
$11.9M |
| 4 |
ASE Group
ASX
|
$7.99M |
| 5 |
Yum China
YUMC
|
$5.17M |
Sector Composition
| 1 | Consumer Discretionary | 39.73% |
| 2 | Technology | 31.74% |
| 3 | Communication Services | 9.52% |
| 4 | Healthcare | 5.08% |
| 5 | Financials | 4.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
226
Dyne Therapeutics
DYN
$2.02B
| $312K | 0.02% |
8,829
-7,446
| -46% | -$263K |
|
227
Twist Bioscience
TWST
$1.55B
| $309K | 0.02% |
6,261
-5,274
| -46% | -$260K |
|
228
NetApp
NTAP
$23.7B
| $308K | 0.02% |
+2,391
| New | +$308K |
|
229
Crinetics Pharmaceuticals
CRNX
$3.35B
| $305K | 0.02% |
6,813
-3,435
| -34% | -$154K |
|
230
CoStar Group
CSGP
$37.9B
| $304K | 0.02% |
4,095
+76
| +2% | +$5.64K |
|
231
Acadia Pharmaceuticals
ACAD
$4.26B
| $301K | 0.02% |
18,528
+40
| +0.2% | +$650 |
|
232
Bristol-Myers Squibb
BMY
$96B
| $299K | 0.02% |
7,190
+840
| +13% | +$34.9K |
|
233
Xcel Energy
XEL
$43B
| $298K | 0.02% |
5,585
+106
| +2% | +$5.66K |
|
234
Nuvalent
NUVL
$5.83B
| $298K | 0.02% |
3,929
-1,207
| -24% | -$91.6K |
|
235
Zoetis
ZTS
$67.9B
| $293K | 0.02% |
1,689
+24
| +1% | +$4.16K |
|
236
Ardelyx
ARDX
$1.57B
| $289K | 0.02% |
39,033
-10,835
| -22% | -$80.3K |
|
237
Arcellx
ACLX
$4.03B
| $288K | 0.02% |
5,212
-774
| -13% | -$42.7K |
|
238
Western Digital
WDC
$31.9B
| $287K | 0.02% |
+5,005
| New | +$287K |
|
239
Coca-Cola Europacific Partners
CCEP
$40.4B
| $286K | 0.02% |
3,922
+101
| +3% | +$7.36K |
|
240
McKesson
MCK
$85.5B
| $284K | 0.02% |
487
-51
| -9% | -$29.8K |
|
241
Intellia Therapeutics
NTLA
$1.29B
| $283K | 0.02% |
12,665
-1,795
| -12% | -$40.2K |
|
242
CVS Health
CVS
$93.6B
| $279K | 0.02% |
4,722
+467
| +11% | +$27.6K |
|
243
First Solar
FSLR
$22B
| $278K | 0.02% |
+1,232
| New | +$278K |
|
244
Amicus Therapeutics
FOLD
$2.46B
| $275K | 0.02% |
27,734
-7,498
| -21% | -$74.4K |
|
245
Keysight
KEYS
$28.9B
| $274K | 0.02% |
2,001
+572
| +40% | +$78.2K |
|
246
Becton Dickinson
BDX
$55.1B
| $272K | 0.02% |
1,165
-12
| -1% | -$2.81K |
|
247
Avidity Biosciences
RNA
$6.48B
| $271K | 0.02% |
6,640
-2,857
| -30% | -$117K |
|
248
Celldex Therapeutics
CLDX
$1.52B
| $269K | 0.01% |
7,258
-1,788
| -20% | -$66.2K |
|
249
Teradyne
TER
$19.1B
| $268K | 0.01% |
+1,809
| New | +$268K |
|
250
Vera Therapeutics
VERA
$1.54B
| $268K | 0.01% |
7,395
-865
| -10% | -$31.3K |
|